Adze Biotechnology Pipeline
Our platform of intravenously and intratumorally deliverable oncolytic immunotherapies enables us to pursue multiple indications across broad patient populations.
Our platform of intravenously and intratumorally deliverable oncolytic immunotherapies enables us to pursue multiple indications across broad patient populations.